Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

T he battle between weight-loss drugs continues. While studies show semaglutide (sold under the brand names Ozempic and ...

Currently, only liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are approved for weight loss, though some other GLP-1 drugs may be prescribed off-label. Keep in mind that ...

The increase in weight loss with ... Reduction Act. Tirzepatide will be protected from inclusion in the negotiation list until 2030, as it was first approved in 2022, while semaglutide has been ...

Others are more direct, recommending peptides for weight loss and describing their experiences using them. These include the usual suspects, like semaglutide and tirzepatide, but also retatrutide ...

“I am taking compounded semaglutide that ... agonist. Tirzepatide is sold under the brand names Mounjaro and Zepbound for T2D treatment and weight loss, respectively. Compounded drugs are ...